Role of prophylactic antibiotics in the prevention of infection after chemotherapy: A literature review

Supportive Cancer Therapy

Volumn 3, Issue 4, 2006, Pages 207-213

  Moon, Sarah ^b   Williams, Sarah ^b   Cullen, Michael ^a,b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Febrile neutropenia; Fluoroquinolones; Resistance; Trimethoprim sulfamethoxazole

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LEVOFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN;

ACUTE LEUKEMIA; ANTIBIOTIC THERAPY; CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEBRILE NEUTROPENIA; HUMAN; INFECTION PREVENTION; LYMPHOMA; META ANALYSIS; MORBIDITY; MORTALITY; SOLID TUMOR; SYSTEMATIC REVIEW;

EID: 33749456800     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2006.n.018     Document Type: Conference Paper

References (22)

1. Leonard RC, Miles D, Thomas R, et al. Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Brit J Cancer 2003; 89:2062-2068.
2. van de Watering MD, de Witte MA, Kremer LC, et al. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer 2005; 41:1372-1382.
3. Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995; 39:445-452.
4. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-751.
5. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996; 23:795-805.
6. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16:1179-1187.
7. Tjan-Heijnen VC, Postmus PE, Ardizzoni A, et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 2001; 12:1359-1368.
8. Cruciani M, Malena M, Bosco O, et al. Reappraisal with meta-analysis of the addition of gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003; 21:4127-4137.
9. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353:977-987.
10. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353:988-998.
11. Crawford J, Wolff DA, Culakova E, et al. First cycle risk of severe and febrile neutropenia in cancer patients receiving systemic chemotherapy: results from a prospective nationwide study. Blood 2004; 104:607a-608a (Abstract #2210).
12. Tjan-Heijnen VC, Caleo S, Postmus PE, et al. Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923). Ann Oncol 2003; 14:248-257.
13. Gafter-Gvili A, Fraser A, Paul M, et al. Meta-analysis: antibiotic prophylaxis-reduces mortality in neutropenic patients. Ann Intern Med 2005; 142(12 pt 1):979-995.
14. Leibovici L, Gafter-Gvili A, Paul M, et al. implications of the evidence for antibiotic prophylaxis for cancer patients with neutropenia: updated meta-analysis. Paper presented at: 16th European Congress of Clinical Microbiology and Infectious Diseases; April 1-4, 2006; Nice, France.
15. Carratala J, Fernandez-Sevilla A, Tubau F, et al. Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996; 40:503-505.
16. Baum HV, Franz U, Geiss HK. Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection 2000; 28:278-281.
17. Nucci M, Spector N, Bueno AP, et al. Quinolone prophylaxis in neutropenic patients: efficacy versus resistance. Oncol Reports 1994; 1:1101-1105.
18. Kern WV. Epidemiology of fluoroquinolone-resistant Escherichia coli among neutropenic patients. Clin Inject Dis 1998; 27:235-237.
19. Kern WV, Andriof E, Oethinger M, et al. Emergence of fluoroquinolone- resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994; 38:681-687.
20. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24:111-118.
21. Oethinger M, Conrad S, Kaifel K, et al. Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers. Antimicrob Agents Chemother 1996; 40:387-392.
22. Goossens H, Ferech M, Vander Stichele R, et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365:579-587.